表观遗传修饰损害糖尿病视网膜病变发生中的线粒体DNA质量控制
研究在高糖孵育人视网膜内皮细胞及链脲佐菌素诱导糖尿病小鼠和糖尿病视网膜病变供体视网膜微血管中,发现Mlh1启动子DNA高甲基化、Dnmt-1结合增加和Sp1结合减少使Mlh1线粒体定位与转录下降,mtDNA错配修复受损;Dnmt抑制剂可减轻上述改变。
要点
- 高糖降低Mlh1线粒体定位,其启动子DNA高甲基化伴Dnmt-1结合增加、Sp1结合减少。
- Dnmt抑制剂减轻Mlh1启动子高甲基化,阻止其基因转录下降和mtDNA错配增加。
- 糖尿病小鼠和糖尿病视网膜病变供体视网膜微血管中Mlh1基因转录下降及启动子DNA高甲基化相似。
核心结论
- Mlh1启动子表观遗传修饰导致其转录下降,线粒体Mlh1积聚减少,无法修复mtDNA错配。
- 作者认为靶向阻止DNA甲基化的治疗有潜力预防或终止mtDNA损伤及糖尿病视网膜病变的发生。
研究设计与样本
- 体外研究:人视网膜内皮细胞在20 mM葡萄糖中孵育,并以5 mM葡萄糖为对照。
- 动物实验:链脲佐菌素诱导糖尿病小鼠,给予或不给予Dnmt抑制剂。
- 人体验证:糖尿病视网膜病变供体视网膜微血管。
主要发现
- 与5 mM葡萄糖相比,高糖降低Mlh1线粒体定位,其启动子DNA高甲基化伴Dnmt-1结合增加、Sp1结合减少。
- Dnmt抑制剂减轻Mlh1启动子高甲基化,阻止其基因转录下降和mtDNA错配增加。
- 小鼠给予Dnmt抑制剂改善糖尿病诱导的Mlh1启动子高甲基化增加及其基因转录下降。
- 糖尿病视网膜病变供体中也观察到Mlh1基因转录下降和启动子DNA高甲基化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diabetes causes dysfunction in the retinal mitochondria and increases base mismatches in their DNA (mtDNA). The enzyme responsible for repairing the base mismatches, MutL homolog 1 (Mlh1), is compromised. Diabetes also favors many epigenetic modifications and activates DNA methylation machinery, and Mlh1 has a CpG-rich promoter. Our aim is to identify the molecular mechanism responsible for impaired mtDNA mismatch repair in the pathogenesis of diabetic retinopathy. METHODS: Human retinal endothelial cells, incubated in 20 mM glucose, were analyzed for mitochondrial localization of Mlh1 by an immunofluorescence technique, Mlh1 promoter DNA methylation by the methylated DNA capture method, and the binding of Dnmt1 and transcriptional factor Sp1 by chromatin immunoprecipitation. The results were confirmed in retinal microvessels from streptozotocin-induced diabetic mice, with or without Dnmt inhibitors, and from human donors with diabetic retinopathy. RESULTS: Compared with cells in 5 mM glucose, high glucose decreased Mlh1 mitochondrial localization, and its promoter DNA was hypermethylated with increased Dnmt-1 binding and decreased Sp1 binding. Dnmt inhibitors attenuated Mlh1 promoter hypermethylation and prevented a decrease in its gene transcripts and an increase in mtDNA mismatches. The administration of Dnmt inhibitors in mice ameliorated a diabetes-induced increase in Mlh1 promoter hypermethylation and a decrease in its gene transcripts. Similar decreases in Mlh1 gene transcripts and its promoter DNA hypermethylation were observed in human donors. CONCLUSIONS: Thus, as a result of the epigenetic modifications of the Mlh1 promoter, its transcription is decreased, and decreased mitochondrial accumulation fails to repair mtDNA mismatches. Therapies targeted to halt DNA methylation have the potential to prevent/halt mtDNA damage and the development of diabetic retinopathy.
引用
- Mohammad G, Radhakrishnan R, Kowluru RA, et al. Epigenetic Modifications Compromise Mitochondrial DNA Quality Control in the Development of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2019. PMID: 31546260. doi:10.1167/iovs.19-27602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。